William Blair Has Bearish Estimate for ABT Q1 Earnings

Abbott Laboratories (NYSE:ABT) – Analysts at William Blair reduced their Q1 2025 earnings per share estimates for Abbott Laboratories in a report released on Thursday, January 23rd. William Blair analyst M. Andrew now expects that the healthcare product maker will earn $1.07 per share for the quarter, down from their prior forecast of $1.10. The consensus estimate for Abbott Laboratories’ current full-year earnings is $4.67 per share. William Blair also issued estimates for Abbott Laboratories’ Q2 2025 earnings at $1.23 EPS, Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $5.15 EPS, Q1 2026 earnings at $1.18 EPS, Q2 2026 earnings at $1.37 EPS, Q3 2026 earnings at $1.49 EPS, Q4 2026 earnings at $1.67 EPS and FY2026 earnings at $5.71 EPS.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11,029,400 billion. During the same period last year, the business posted $1.19 EPS. The business’s revenue was up 7.2% compared to the same quarter last year.

A number of other research firms have also recently issued reports on ABT. Jefferies Financial Group increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research report on Thursday, October 17th. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday. UBS Group increased their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday. Mizuho increased their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research report on Thursday, October 17th. Finally, Sanford C. Bernstein increased their price objective on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $132.50.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $123.17 on Friday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $114.91 and a two-hundred day moving average price of $113.08. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $123.23. The company has a market cap of $213.62 billion, a P/E ratio of 37.44, a PEG ratio of 2.50 and a beta of 0.73.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.92%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.85%.

Institutional Investors Weigh In On Abbott Laboratories

Large investors have recently modified their holdings of the stock. Groupama Asset Managment increased its stake in shares of Abbott Laboratories by 22.2% during the 3rd quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 41,557 shares during the last quarter. Future Financial Wealth Managment LLC purchased a new position in Abbott Laboratories in the 3rd quarter valued at approximately $31,000. Peterson Financial Group Inc. purchased a new position in Abbott Laboratories in the 3rd quarter valued at approximately $32,000. Valued Wealth Advisors LLC grew its stake in Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares in the last quarter. Finally, Highline Wealth Partners LLC purchased a new position in Abbott Laboratories in the 3rd quarter valued at approximately $37,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.